Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

B936ede5-2834-4507-aff2-da873230567d - samples

ABSTRACT: Data from NABUCCO cohort 1 (NCT03387761). This dataset includes Tumor mutational burden (TMB) calculated on bladder tumor pre-treatment DNA sequencing data (n=24). Details about the Tumor Mutational Burden calculation can be found on the Methods section from the Nature Medicine paper (https://doi.org/10.1038/s41591-020-1085-z)

PROVIDER: EGAD00001006851 | EGA |

REPOSITORIES: EGA

ACCESS DATA

Json Xml

Similar Datasets

8ab494b0-a700-4578-9ecc-943c4df785e7 - samples

Project description:Data from NABUCCO cohort 1 (NCT03387761). This dataset includes the pre-treatment PD-L1 staining on tumor samples (n=24). Details about the PD-L1 staining can be found on the paper (https://doi.org/10.1038/s41591-020-1085-z)

| EGAD00001006856 | EGA

14b69200-68f9-43e1-b8fc-19b810ecdbbe - samples

Project description:Data from NABUCCO cohort 1 (NCT03387761). This dataset includes the Transcript read counts derived from the RNA sequencing data. The samples are pre-treatment (n=18) and post-treatment (n=18), and not all samples are paired. The data processing pipeline can be found on the Methods section from the Nature Medicine paper (https://doi.org/10.1038/s41591-020-1085-z)

| EGAD00001006854 | EGA

294264a0-6fff-481a-873e-31e55f1c19ea - samples

Project description:Data from NABUCCO cohort 1 (NCT03387761). This dataset includes the Response labels used for the analysis of the data. Details about the clinical definitions of Response can be found on the paper (https://doi.org/10.1038/s41591-020-1085-z)

| EGAD00001006853 | EGA

Project description:Tumor mutational burden and aneuploidy

| PRJNA610493 | ENA

5c8d51a7-6ae9-4ebd-aa2e-826d72764981 - samples

Project description:Data from NABUCCO cohort 2 (NCT03387761). This dataset includes Whole exome DNA sequencing on bladder tumor samples matched with blood samples for patients from NABUCCO Cohort 2 (Cohort 2A and Cohort 2B). The data is pre-treatment

| EGAD00001009864 | EGA

RNA profiling of PB-020 and anti-PD-1 antibody treated MC38 tumor tissue

Project description:Immune surveillance escaping is essential for survival of original tumor. Considering PB-020’s good pharmacokinetic properties, combined effect of PB-020 and immunotherapy drugs is worth studying. As PB-020 can effectively suppress mouse colorectal cancer cell lines in cell culture, we tested the effect of combining PB-020 with the anti-PD-1 monoclonal antibody RMP1-14 on the growth of subcutaneously implanted MC38 cells to C57BL/6 mice as a syngeneic mouse model of colorectal cancer. To clarify the molecular mechanism underling this anti-cancer therapy, we executed RNA sequencing of tumor sample obtained from the experiment above.

2022-12-14 | GSE189469 | GEO

Characterization of tumor mutational burden in LKB1 mutant lung tumors

Project description:Characterization of tumor mutational burden in LKB1 mutant lung tumors

| PRJNA564852 | ENA

Project description:Characterization of tumor mutational burden in LKB1 mutant lung tumors

| PRJNA564395 | ENA

a3087794-0009-4fac-a2e0-773dd69fc822 - samples

Project description:Data from NABUCCO cohort 1 (NCT03387761). This dataset includes Whole exome DNA sequencing on bladder tumor samples (n=24) matched with blood samples (n=24). The data is pre-treatment.

| EGAD00001006850 | EGA

Abbott2021 - Prediction of Immunotherapy Response in Melanoma through Combined Modeling of NB and Immune-Related Resistance Mechanisms

Project description:In this manuscript, the authors had hypothesized a multi-dimensional approach modeling of both tumor and immune-related molecular mechanisms would better predict immune checkpoint blockade (ICB) response than simpler mutation-focused biomarkers, such as tumor mutational burden (TMB). The authors showed that the predictive power increases with deeper modeling of neoantigens and immune-related resistance mechanisms of ICB. The neoantigen burden score (NBS) and composite neoantigen presentation score (NEOPS) mentioned in the transcript was fully reproduced. Internally they used XGBoost algorithm to generate the results and the same is provided as dataset file. That is, the dataset provided here demonstrates that their integrative approach outperformed single-analyte biomarkers such as those found in cohort of patients with late-stage melanoma. This model is now addresses the issues in reproducing itself which was caused by version changes and deprecation of some R packages. It uses checkpoint package, which acts as a time machine for CRAN packages thereby promoting FAIReR sharing of ML models.

2024-07-23 | MODEL2407210001 | BioModels

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data